In male ICR mice, hippocampal Cangrelor pretreatment followed by LPS significantly increased target-quadrant time and platform location crossings compared with vehicle plus LPS. In male mice undergoing regional ischaemia and reperfusion, intravenous Cangrelor reduced infarct size compared with saline vehicle. In Apoe-deficient mice undergoing ultrasound-induced plaque rupture, intravenous Cangrelor was associated with more emboli shed from thrombi than in control mice. [2,1,3]
Spatial memory outcomes in mice with LPS-induced cognitive impairment
Animal study · Male Institute of Cancer Research (ICR) mice; LPS-induced cognitive impairment; n = 12 mice/group [2]
Male ICR mice received Cangrelor pretreatment by microinfusion into bilateral hippocampal DG regions before LPS administration. Compared with vehicle plus LPS, Cangrelor plus LPS significantly increased the percentage of time spent in the target quadrant and the number of platform location crossings.
Conditions shared by the study groups
- Route
- microinfused into bilateral DG regions of the hippocampus
- Treatment course
- every day for 3 weeks; followed by LPS (0.25 mg/kg, i.p.) or its vehicle was administered for 7 days
- Cangrelor 2.0 μg; 4.0 μg
- Model: Male Institute of Cancer Research (ICR) mice; LPS-induced cognitive impairment; n = 12 mice/group
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Cangrelor
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Animals (S1); Materials and methods > LPS-induced cognitive impairment mouse model > The drug treatment experiment (S25, S30, S34); Results > Inhibition of GPR17 with cangrelor attenuates cognitive impairment induced by LPS in mice (S164, S174); Fig. 3 legend (S292, S301)
The percentage of total time spent in the target quadrant during the probe trial: The percentage of total time spent in the target quadrant during the probe trial; comparator: vehicle plus LPS (Veh + LPS) — Materials and methods > LPS-induced cognitive impairment mouse model > The drug treatment experiment (S25); Results > Inhibition of GPR17 with cangrelor attenuates cognitive impairment induced by LPS in mice (S174); Fig. 3 legend (S301)
Cangrelor 2.0 μg; 4.0 μg · Materials and methods > LPS-induced cognitive impairment mouse model > The drug treatment experiment (S25, S34); Results > Inhibition of GPR17 with cangrelor attenuates cognitive impairment induced by LPS in mice (S174); Fig. 3 legend (S292)
Infarct size following regional ischaemia and reperfusion in mice
Animal study · C57BL6 male mice [1]
Male mice undergoing regional ischaemia and reperfusion received intravenous Cangrelor by bolus infusion followed by continuous infusion during reperfusion. Infarct size was lower with Cangrelor than with the saline vehicle control.
Conditions shared by the study groups
- Route
- intravenous
- Treatment course
- Ten minutes prior to the onset of reperfusion; 10 min bolus infusion; continuous infusion; upon the onset and for the duration of reperfusion; 35 min injurious regional ischaemia, followed by 2 h reperfusion
- Vehicle
- normal saline
- Cangrelor 60 μg/kg; 6 μg/kg/min
- Model: C57BL6 male mice
Methods and source locations
Compound reported in the paper: Cangrelor
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > In-Vivo Mouse Ischaemia/Reperfusion (S8, S13, S16, S17, S18); Results > Cangrelor is Protective In-Vivo, But Not Ex-Vivo (S42); Fig. 1 legend (S54)
infarct size: infarct size; comparator: vehicle (normal saline) — Methods > In-Vivo Mouse Ischaemia/Reperfusion (S17, S18); Results > Cangrelor is Protective In-Vivo, But Not Ex-Vivo (S42)
Cangrelor 60 μg/kg; 6 μg/kg/min · Methods > In-Vivo Mouse Ischaemia/Reperfusion (S16, S17); Results > Cangrelor is Protective In-Vivo, But Not Ex-Vivo (S42)
Embolus shedding following plaque rupture in mice
Animal study · Apoe −/− mice on C57BL/6 background [3]
Apoe-deficient mice received continuous intravenous Cangrelor beginning before ultrasound treatment. With Cangrelor present, more fluorescent emboli were shed from thrombi after plaque rupture than in control mice.
Conditions shared by the study groups
- Route
- intravenously
- Treatment course
- continuously infused; started at 15 min before ultrasound treatment
- Vehicle
- 5% mannitol in saline
- Cangrelor 3 µg/kg/min
- Model: Apoe −/− mice on C57BL/6 background
Methods and source locations
Compound reported in the paper: Cangrelor
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Animals (S9, S10); Materials and Methods > In vivo plaque rupture and measurement of thrombus formation (S15, S20); Materials and Methods > In vivo administration of P2Y12 antagonist and blood collection (S30); Results > Inhibition of mouse P2Y12 receptors causes unstable thrombus formation after rupture of an atherosclerotic plaque (S70, S82); Figure 1 legend (S129, S131, S141)
Number of fluorescent emboli shed during 3 min after plaque rupture: Number of fluorescent emboli shed during 3 min after plaque rupture; comparator: vehicle solution — Results > Inhibition of mouse P2Y12 receptors causes unstable thrombus formation after rupture of an atherosclerotic plaque (S82); Figure 1 legend (S131, S141)
Cangrelor 3 µg/kg/min · Materials and Methods > In vivo administration of P2Y12 antagonist and blood collection (S30); Results > Inhibition of mouse P2Y12 receptors causes unstable thrombus formation after rupture of an atherosclerotic plaque (S82); Figure 1 legend (S131)